Recombinant Cynomolgus/Rhesus Siglec-3/CD33 Fc Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10885-SL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10885-SL-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

XP_045235686.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all Siglec-3/CD33 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived Siglec-3/CD33 protein
Cynomolgus Monkey/Rhesus Macaque Siglec-3/CD33
(Met16-Gly248)
Accession # XP_045235686.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met16

Predicted Molecular Mass

52 kDa

SDS-PAGE

68-79 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Cynomolgus Monkey/Rhesus Macaque Siglec-3/CD33 Fc Chimera (Catalog # 10885-SL) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human Galectin-3BP/MAC-2BP (Catalog # 2226-GAB) binds with an ED50 of 0.15-1.20 µg/mL.

Scientific Data Images for Recombinant Cynomolgus/Rhesus Siglec-3/CD33 Fc Protein, CF

Recombinant Cynomolgus Monkey/Rhesus Macaque Siglec‑3/CD33 Fc Chimera Protein Binding Activity.

When Recombinant Cynomolgus Monkey/Rhesus Macaque Siglec-3/CD33 Fc Chimera (Catalog # 10885-SL) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human Galectin-3BP/MAC-2BP (2226-GAB) binds with an ED50 of 0.15-1.20 µg/mL.

Recombinant Cynomolgus Monkey/Rhesus Macaque Siglec‑3/CD33 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey/Rhesus Macaque Siglec‑3/CD33 Fc Chimera Protein (Catalog # 10885-SL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 68-79 kDa and 140-160 kDa, respectively.

Formulation, Preparation and Storage

10885-SL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Siglec-3/CD33

Sialic acid-binding Ig-like lectin 3 (Siglec-3), also known myeloid cell surface antigen CD33 (CD33), is a I-type (Ig-type) lectin belonging to the sialoadhesin subclass of the immunoglobulin superfamily (1). Siglecs are characterized by an N-terminal Ig-like V-type domain, which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains in the extracellular domain (ECD). Fourteen human and nine mouse Siglecs have been characterized and are divided into 2 families: CD33 related and evolutionarily conserved (1-3). Mature Siglec-3 consists of an ECD with one Ig-like V-type domain and one Ig-like C2 domain, a single transmembrane and a cytoplasmic tail containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (3). Within the ECD, cynomolgus/rhesus Siglec-3 shares 89% amino acid sequence identity with human Siglec-3. An isoform of Siglec-3 lacking the N-terminal V-type domain, generated by alternative splicing, has been identified in humans (4). Each Siglec family member has a distinct preference for binding the various types of sialylated glycans found on the surface of mammalian cells and they most likely evolved to regulate host immune responses via the recognition of self-glycans (6). Siglec-3 is a disulfide-linked homodimer expressed on neutrophils, monocytes, macrophages and dendritic cells (2). Siglec-3 may be implicated in the regulation of both the innate but also the adaptive immunity and human Siglec-3 continues to be a therapeutic target for the treatment of acute myeloid leukemia and is a high potential risk factor for Alzheimer's (5). Siglec-3's ligands have yet to be classified, however terminal epitope preferences are conserved between Siglec-3 and Siglec-9 when binding to glycans (7). R&D Systems in-house testing indicates that Siglec-3 binds to LGALS3BP, consistent with the demonstrated functional interactions between other members of these protein families (8).

References

  1. Bhattacherjee, A. et al. (2021) Mol. Neurodegener. 16:19.
  2. Murch, S. et al. (2020) Medical Hypotheses. 144:110168.
  3. Hernandez-Caselles, T. et al. (2019) J. Immunol. Res. 2019:6032141.
  4. Hernández-Caselles, T. et al. (2006) J Leukoc Biol. 79:46
  5. Malik, et al. (2013) J. Neurosci. 33:13320
  6. Paulson, J. et al. (2012) Ann. N. Y. Acad. Sci. 1253:37.
  7. Wang, S. et al. (2021) Front Mol. Biosci. 8:645999.
  8. Laubli, H. et al. (2014) J. Biol. Chem. 289:33481.

Long Name

Sialic Acid Binding Ig-like Lectin 3

Alternate Names

CD33, gp67, Siglec3

Entrez Gene IDs

945 (Human); 12489 (Mouse); 102117580 (Cynomolgus Monkey)

Gene Symbol

CD33

UniProt

XP_045235686.1

Additional Siglec-3/CD33 Products

Product Documents for Recombinant Cynomolgus/Rhesus Siglec-3/CD33 Fc Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus/Rhesus Siglec-3/CD33 Fc Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.